Cor Vasa 2023, 65(3):489-495 | DOI: 10.33678/cor.2022.126

Gut microbiota changes in nonalcoholic fatty liver disease and concomitant coronary artery disease

Galyna Fadieienko, Oleksiy Gridnyev, Olena Kurinna, Nataliia Chereliuk
Study of GIS Diseases and their Comorbidity with Non-Communicable Diseases Department, Governmental Institution "L.T. Malaya National Institute of Therapy of the National Academy of Medical Sciences of Ukraine", Kharkiv, Ukraine

Background and the research aim: Nonalcoholic fatty liver disease (NAFLD) bears serious economic consequences for the health care system worldwide and Ukraine, in particular. Cardiovascular diseases (CVD) are the main cause of mortality in NAFLD patients. Changes in the gut microbiota composition can be regarded as a potential mechanism of CVD in NAFLD patients. The research aim was the investigation changes in major gut microbiota phylotypes, Bacteroidetes, Firmicutes, and Actinobacteria with quantification of Firmicutes/Bacteroidetes in NAFLD patients with concomitant CVD.

Materials and methods: There were 109 NAFLD subjects (25 with concomitant arterial hypertension [AH] and 24 with coronary artery disease [CAD]) enrolled. The gut microbiota composition was assessed by qPCR. Results and conclusions: There was a marked tendency towards an increase in the concentration of Bacte- roidetes (by 37.11% and 21.30%, respectively) with a decrease in Firmicutes (by 7.38% and 7.77%, respectively) found in both groups with comorbid CAD and AH with the identified changes not reaching a statistical significance. A statistically significant decrease in the concentration of Actinobacteria was revealed in pa- tients with NAFLD with concomitant CAD at 41.37% (p <0.05) as compared with those with an isolated NAFLD. In patients with concomitant AH, the content of Actinobacteria dropped by 12.35%, which was statistically insignificant. There were changes found in the intestinal microbiota composition, namely decrease in Actinobacteria in patients with CAD, which requires further research.

Keywords: Cardiovascular diseases, Coronary artery disease, Gut microbiota, Nonalcoholic fatty liver disease

Received: October 4, 2022; Revised: November 21, 2022; Accepted: November 26, 2022; Published: June 20, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fadieienko G, Gridnyev O, Kurinna O, Chereliuk N. Gut microbiota changes in nonalcoholic fatty liver disease and concomitant coronary artery disease. Cor Vasa. 2023;65(3):489-495. doi: 10.33678/cor.2022.126.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020;5:16. Go to original source...
    2. Nadasdi A, Somogyi A, Igaz P, Firneisz G. [Non-alcoholic fatty liver disease - a summary and update based on the EASL-EASD-EASO Clinical Practice Guidelines of 2016.] Orv Hetil 2018;159:1815-1830. Article in Hungarian. Go to original source... Go to PubMed...
    3. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-2273. Go to original source... Go to PubMed...
    4. Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013;58:3017-3023. Go to original source...
    5. Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020;69:1691-1705. Go to original source... Go to PubMed...
    6. Paik JM, Henry L, De Avila L, et al. Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. Hepatol Communic 2019;3:1459-1471. Go to original source... Go to PubMed...
    7. Targher G, Byrne CD, Lonardo A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol 2016;65:589-600. Go to original source... Go to PubMed...
    8. Barik A, Shah RV, Spahillari A, et al. Hepatic steatosis is associated with cardiometabolic risk in a rural Indian population: A prospective cohort study. Int J Cardiol 2016;225:161-166. Go to original source...
    9. Ma J, Li H. The role of gut microbiota in atherosclerosis and hypertension. Front Pharmacol 2018;9:1082. Go to original source...
    10. Tana C, Ballestri S, Ricci F, et al. Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Intern J Envir Res Public Health 2019;16:3104. Go to original source...
    11. Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021;110:921-937. Go to original source... Go to PubMed...
    12. Karbach SH, Schonfelder T, Brandao I, et al. Gut microbiota promote angiotensin II-induced arterial hypertension and vascular dysfunction. J Am Heart Assoc 2016;5:e003698. Go to original source...
    13. Kim S, Goel R, Kumar A, et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci (Lond) 2018;132:701-718. Go to original source... Go to PubMed...
    14. Tang WHW, Li DY, Hazen SL. Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol 2019;16:137-154. Go to original source... Go to PubMed...
    15. Kazemian N, Mahmoudi M, Halperin F, et al. Gut microbiota and cardiovascular disease: opportunities and challenges. Microbiome 2020;8:36. Go to original source... Go to PubMed...
    16. Marchesini G. Response to: Comment to "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". J Hepatol 2016;64:1388-1402. Go to original source... Go to PubMed...
    17. Joseph J, Velasco A, Hage FG, Reyes E. Guidelines in review: Comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary artery disease. J Nuclear Cardiol 2018;25:509-515. Go to original source... Go to PubMed...
    18. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eu Heart J 2018;39:3021-3104. Go to original source...
    19. Bacchetti De Gregoris T, Aldred N, Clare AS, Burgess JG. Improvement of phylum- and class-specific primers for real-time PCR quantification of bacterial taxa. J Microbiol Methods 2011;86:351-356. Go to original source... Go to PubMed...
    20. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009;457:480-484. Go to original source... Go to PubMed...
    21. Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med 2019;11:e9302. Go to original source... Go to PubMed...
    22. Emoto T, Yamashita T, Kobayashi T, et al. Characterization of gut microbiota profiles in coronary artery disease patients using data mining analysis of terminal restriction fragment length polymorphism: gut microbiota could be a diagnostic marker of coronary artery disease. Heart Vessels 2017;32:39-46. Go to original source... Go to PubMed...
    23. Gui T, Shimokado A, Sun Y, et al. Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediat Inflam 2012;2012:693083. Go to original source... Go to PubMed...
    24. Drosos I, Tavridou A, Kolios G. New aspects on the metabolic role of intestinal microbiota in the development of atherosclerosis. Metabolism 2015;64:476-481. Go to original source...
    25. Gregory JC, Buffa JA, Org E, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem 2015;290:5647-5660. Go to original source...
    26. Jie Z, Xia H, Zhong SL, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun 2017;8:845. Go to original source... Go to PubMed...
    27. Cui L, Zhao T, Hu H, et al. Association Study of Gut Flora in Coronary Heart Disease through High-Throughput Sequencing. BioMed Res Intern 2017;2017:3796359. Go to original source...
    28. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. JAMA 2005;293:2641-2647. Go to original source... Go to PubMed...
    29. Kasahara K, Tanoue T, Yamashita T, et al. Commensal bacteria at the crossroad between cholesterol homeostasis and chronic inflammation in atherosclerosis. J Lipid Res 2017;58:519-528. Go to original source... Go to PubMed...
    30. Schoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocrine Metabolic Disorders 2019;20:461-472. Go to original source... Go to PubMed...
    31. Ganesan K, Chung SK, Vanamala J, Xu B. Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes. Intern J Molecul Sci 2018;19:3720. Go to original source... Go to PubMed...
    32. Trøseid M, Andersen G, Broch K, et al. The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions. EBioMedicine 2020;52:102649. Go to original source... Go to PubMed...
    33. Anandan R, Dharumadurai D, Manogaran GP. Actinobacteria Basics and Biotechnological Applications. In: Dhanasekaran D, Jiang Y, editors. An Introduction to Actinobacteria. BoD-Books on Demand IntechOpen 2016.
    34. Jonsson AL, Hallenius FF, Akrami R, et al. Bacterial profile in human atherosclerotic plaques. Atherosclerosis 2017;263:177-183. Go to original source...
    35. Tuomisto S, Huhtala H, Martiskainen M, et al. Age-dependent association of gut bacteria with coronary atherosclerosis: Tampere Sudden Death Study. PloS one 2019;14:e0221345. Go to original source... Go to PubMed...
    36. Li L, Shi M, Salerno S, et al. Microbial and metabolomic remodeling by a formula of Sichuan dark tea improves hyperlipidemia in apoE-deficient mice. PloS one 2019;14:e0219010. Go to original source... Go to PubMed...
    37. Mach N, Fuster-Botella D. Endurance exercise and gut microbiota: A review. J Sport Health Sci 2017;6:179-197. Go to original source...
    38. Kim D, Vazquez-Montesino LM, Li AA, et al. Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease. Hepatology 2020;72:1556-1568. Go to original source... Go to PubMed...
    39. Zhuang Z, Gao M, Yang R, et al. Association of physical activity, sedentary behaviours and sleep duration with cardiovascular diseases and lipid profiles: a Mendelian randomization analysis. Lipids Health Dis 2020;19:86. Go to original source... Go to PubMed...
    40. Muscogiuri G, Cantone E, Cassarano S, et al. Gut microbiota: a new path to treat obesity. Intern J Obesity Suppl 2019;9:10-19. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes